Commencement of manufacturing of the final drug product (oral tablets) for the Stargardt disease treatment candidate emixustat hydrochloride (Retakubo) toward compassionate access authorization in France
Kubota Vision Inc. (a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co.,Ltd.)
The final drug product (oral tablets) for the Stargardt disease treatment candidate emixustat hydrochloride (Retakubo) for France
Related procedures
Patient-specific application and approval procedures under compassionate access (AAC)
French National Agency for Medicines and Health Products Safety (ANSM)
We expect the impact on our financial results to be minor.
Kubota Vision, in collaboration with KÔL, will continue advancing preparations to make Retakubo available in France, including activities to support the relevant regulatory procedures.
The Company will promptly disclose any matters that arise requiring disclosure.
| Item | Details |
|---|---|
| Event name | Commencement of manufacturing of the final drug product (oral tablets) for the Stargardt disease treatment candidate emixustat hydrochloride (Retakubo) toward compassionate access authorization in France |
| Subject Entity | Kubota Vision Inc. (a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co.,Ltd.) |
| Target Locations / Products | The final drug product (oral tablets) for the Stargardt disease treatment candidate emixustat hydrochloride (Retakubo) for France |
| Impact on Earnings Forecast | We expect the impact on our financial results to be minor. |
| Type of litigation or proceeding | Patient-specific application and approval procedures under compassionate access (AAC) |
| Court or authority | French National Agency for Medicines and Health Products Safety (ANSM) |
| Outlook | Kubota Vision, in collaboration with KÔL, will continue advancing preparations to make Retakubo available in France, including activities to support the relevant regulatory procedures. |
| Planned follow-up disclosure | The Company will promptly disclose any matters that arise requiring disclosure. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The final drug product is being manufactured in preparation for providing Retakubo to patients under France's compassionate access program. Approval from the French National Agency for Medicines and Health Products Safety (ANSM) is required for each patient-specific application.